![The Tesla Model 3](https://www.morningstar.co.uk/static/UploadManager/Assets/Tesla%20model_3_red.jpg)
Our charts show why Tesla's influence in the marketplace is growing
![USA sign on a red car](https://images.contentstack.io/v3/assets/blt4eb669caa7dc65b2/bltc42522d07ff5f5fd/65969df8a2c41fae76db19a4/USA_UK.jpg)
A soft landing is in sight. But could the economic slowdown go too far?
![eagle](https://images.contentstack.io/v3/assets/blt4eb669caa7dc65b2/blt14c13707e5390376/65b0f9510b2014daca40fc8c/Eagle_UK_Main.jpg)
Our latest economic forecast for US interest rates, inflation, and GDP growth
-
Are FTSE Mining Companies Cheap Right Now?
Mining companies are operating in a challenging environment but could now be the time to top up o...
-
Advice for George Osborne and Stock Market Regrets
THE WEEK: Morningstar columnist Rodney Hobson provides two pieces of advice to George Osborne, an...
-
How to Find Solid Dividend-Paying Stocks
Businesses that have competitive advantages within their industry are good candidates for dividen...
-
10 Top-Performing Funds in the UK
Morningstar reveals the top 10 best performers over the last five years
-
Fund Research: Europe’s Shining Stars
Morningstar OBSR reveals the top funds for investors seeking exposure to European equities
-
NatWest Shares Up as Profits Beat Expectations
The bank also announced a deal with Metro Bank, raised its guidance, and increased its dividends
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
With revenue growth, increased operating margins, but a high valuation, here’s what we think of N...
-
Going into Earnings, is Apple Stock a Buy, Sell, or Hold?
We'll be watching iPhone revenue, gross margins, and services growth when Apple reports its earni...
-
Unilever Earnings: Growth in a Challenging Market
Despite growth, Morningstar's Fair Value Estimate for the consumer goods giant stock is unchanged
-
AstraZeneca Earnings: Steady Outlook but Growth Could Slow
Morningstar analysts think the UK's biggest company has a well-positioned broad drug portfolio wh...